Signal transduction pathways in acute myetoid leukemia

Promotie: mw. L. Han, 13.15 uur, Academiegebouw, Broerstraat 5, Groningen

Proefschrift: Signal transduction pathways in acute myetoid leukemia

Promotor(s): prof.dr. E. Vellenga

Faculteit: Medische Wetenschappen

Contact: via de persvoorlichters van het UMCG, tel. 050-361 2200, e-mail: voorlichting bvl.umcg.nl

Signal transduction pathways in acute myetoid leukemia

Acute myeloid leukemia (AML) is characterized by the uncontrolled accumulation of abnormal white blood cells in the bone marrow that replace normal blood cells, including red blood cells, platelets and normal white blood cells. The symptoms include fatigue, shortness of breath, bleeding, and high risk of infection. Emerging studies consider that leukemic stem cells (LSCs) initiate and maintain AML, and their quiescent state contributes to resistance of chemotherapy. A number of abnormal signaling pathways have been identified in AML LSCs. A novel inhibitor dasatinib was demonstrated to be a potential inhibitor in a subgroup of AML.